HUMA

Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte, Inc. (HUMA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
B-
Factor Score 3.0 / 5.0
Profitability
D-
Factor Score 0.7 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.2
EV / EBITDA -1.5
Rev Growth YoY 34.9%
Gross Margin 0.0%
Price Return 3M 7.6%
Price Return 12M -56.1%
Catalyst Signal 0.00
Market Cap $164.4M
TTM Revenue $2.1M
Price / Sales 77.5
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) B- (3.0) D- (0.7) C- (1.9) C+ (2.6) C (2.2)
2026-11-05 C+ (2.7) B (3.2) D- (0.7) D (1.3) C+ (2.7) C- (2.1)
2026-10-29 C+ (2.6) B- (3.1) F (0.7) D (1.5) C+ (2.7) C- (2.1)
2026-10-22 C+ (2.7) B- (3.1) F (0.7) D+ (1.6) C+ (2.6) C- (2.1)
2026-10-15 C+ (2.7) B- (3.1) F (0.7) D (1.3) C+ (2.6) C- (2.1)
Page 1 of 6